Veru (VERU) closed at $2.09 on November 13, 2026, down 1.4% from the previous close, on volume of 86,625 shares (30-day average 189,958).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
No headlines found.
Globe Newswire (Mon, 9-Nov 8:30 AM ET)
Globe Newswire (Tue, 8-Sep 8:17 AM ET)
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
Globe Newswire (Wed, 2-Sep 8:30 AM ET)
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Veru trades on the NASDAQ stock market under the symbol VERU.
As of November 13, 2026, VERU stock price declined to $2.09 with 86,625 million shares trading.
VERU has a beta of 1.21, meaning it tends to be more sensitive to market movements. VERU has a correlation of 0.06 to the broad based SPY ETF.
VERU has a market cap of $35.64 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, VERU traded as high as $19.20 and as low as $2.04.
The top ETF exchange traded funds that VERU belongs to (by Net Assets): VTI, VXF, IWC.
VERU has underperformed the market in the last year with a price return of -16.7% while the SPY ETF gained +13.4%. VERU has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.6% and -4.6%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
VERU support price is $2.04 and resistance is $2.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERU shares will trade within this expected range on the day.
